Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Share-based Compensation (2017 - 2025)

Historic Share-based Compensation for Denali Therapeutics (DNLI) over the last 9 years, with Q3 2025 value amounting to $25.1 million.

  • Denali Therapeutics' Share-based Compensation rose 110.62% to $25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $100.8 million, marking a year-over-year decrease of 291.75%. This contributed to the annual value of $102.9 million for FY2024, which is 483.25% down from last year.
  • Latest data reveals that Denali Therapeutics reported Share-based Compensation of $25.1 million as of Q3 2025, which was up 110.62% from $25.4 million recorded in Q2 2025.
  • Over the past 5 years, Denali Therapeutics' Share-based Compensation peaked at $28.1 million during Q1 2023, and registered a low of $21.0 million during Q3 2021.
  • Moreover, its 5-year median value for Share-based Compensation was $25.1 million (2025), whereas its average is $24.8 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first surged by 9497.45% in 2021, then plummeted by 962.64% in 2025.
  • Quarter analysis of 5 years shows Denali Therapeutics' Share-based Compensation stood at $22.1 million in 2021, then increased by 14.05% to $25.2 million in 2022, then rose by 3.18% to $26.0 million in 2023, then decreased by 3.5% to $25.1 million in 2024, then increased by 0.23% to $25.1 million in 2025.
  • Its Share-based Compensation stands at $25.1 million for Q3 2025, versus $25.4 million for Q2 2025 and $25.2 million for Q1 2025.